Neoadjuvant Chemotherapy with or Without Nintedanib for Advanced Epithelial Ovarian Cancer: Lessons from the GINECO Double-Blind Randomized Phase II CHIVA Trial. Gwenael Ferron , Gaetan De Rauglaudre , Stephanie Becourt , Nicolas Delanoy , Florence Joly , Alain Lortholary , Benoit You , Patrick Bouchaert , Emmanuelle Malaurie , Sebastien Gouy , Marie-Christine Kaminsky , Jerome Meunier , Jerome Alexandre , Dominique Berton , Nadine Dohollou , Coraline Dubot , Anne Floquet , Laure Favier , Laurence Venat-Bouvet , Michel Fabbro , Christophe Louvet , Jean-Pierre Lotz , Sophie Abadie-Lacourtoisie , Christophe Desauw , Francesco Del Piano , Marianne Leheurteur , Nathalie Bonichon-Lamichhane , Mansour Rastkhah , Philippe Follana , Justine Gantzer , Isabelle Ray-Coquard , Eric Pujade-Lauraine GYNECOLOGIC ONCOLOGY（2023）
Key words
Anti-angiogenic, Interval debulking surgery, Neoadjuvant, Nintedanib, Ovarian cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
